A nurse is caring for a client with stage IIB non-small cell lung cancer who is receiving concurrent chemoradiotherapy and has fatigue, decreased appetite, and mild skin irritation at the radiation site. Which nursing intervention should be the priority during this treatment phase?

Monitoring for pneumonitis is the priority as it is a life-threatening complication of concurrent chemoradiotherapy for lung cancer. Other options manage symptoms but do not address the most urgent risk.

Clinical Context and Priority Setting

The client has stage IIB non-small cell lung cancer (NSCLC) and is undergoing concurrent chemoradiotherapy (CCRT). The reported symptoms—fatigue, decreased appetite, and mild skin irritation—are expected side effects of this treatment modality. However, when establishing nursing priorities during active CCRT, the nurse must apply a physiological risk-based framework. The most immediate, life-threatening complication associated with thoracic radiation is radiation pneumonitis, an acute inflammatory response of the lung parenchyma to radiation exposure.

Why Respiratory Assessment is the Priority

Radiation pneumonitis typically develops 1 to 3 months after completing radiotherapy, but the inflammatory cascade begins during treatment. Early signs can be subtle and easily mistaken for fatigue or general deconditioning. Monitoring for pneumonitis directly addresses the "Airway and Breathing" components of the ABC (Airway, Breathing, Circulation) priority framework, which takes precedence over nutritional support, skin integrity, or nausea management in a client who is currently stable but at risk for rapid respiratory decline. The rationale is grounded in the pathophysiology: ionizing radiation damages type II pneumocytes and vascular endothelial cells, triggering a release of pro-inflammatory cytokines. This leads to interstitial edema, impaired gas exchange, and, if unrecognized, progressive fibrosis.

The critical nature of this complication is underscored by the clinical context of the provided evidence. While the studies focus on the consolidation phase with durvalumab, they highlight that the risk of symptomatic radiation pneumonitis (SRP) is a significant, dose-limiting toxicity that begins with the radiation delivered during the CCRT phase ^[2]. A client's baseline frailty and inflammatory status, which can be exacerbated by poor nutrition, can increase susceptibility to SRP ^[2]. Therefore, while nutritional interventions (option 2) are important for long-term treatment tolerance, they do not address an immediate, potentially fatal physiological threat. Similarly, skin care (option 3) and antiemetic timing (option 4) are valid comfort and safety interventions, but they are secondary to a focused respiratory assessment when the risk of pneumonitis is present.

Integrating Evidence into the Nursing Action

The nurse’s priority intervention—monitoring respiratory status every 4 hours—is a direct application of surveillance for SRP. The assessment should include auscultation for fine crackles, evaluation of respiratory rate and effort, and pulse oximetry. A non-productive cough or low-grade fever can be an early, insidious presentation. The research context reinforces that treatment completion and outcomes are heavily influenced by the ability to manage and detect such toxicities early. Non-completion of subsequent therapy has been associated with poor pretreatment inflammatory and nutritional markers, which are physiological states worsened by uncontrolled pneumonitis . Furthermore, the safety profiles of various CCRT regimens consistently identify pneumonitis as a key adverse event requiring vigilant monitoring, a principle that remains constant even as consolidation therapies evolve [3, 4]. By prioritizing respiratory assessment, the nurse is not merely performing a task but is actively engaging in early detection of a complication that could compromise the client’s entire treatment trajectory and survival.